DDInter833 DDInter231
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric disorders, such as post-traumatic stress disorder.
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Tripelennamine
Tripelennamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexpiprazole
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Metformin
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexpiprazole
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Clofedanol
Clofedanol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexpiprazole
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Diphenhydramine
Diphenhydramine {u} may lead to a major life threatening interaction when taken with {v} Brexpiprazole
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Abdominal pain upper {u} (Side Effect) is caused by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Brexpiprazole
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Tripelennamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Metformin (Compound) and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may lead to a major life threatening interaction when taken with Brexpiprazole
Glycerol phenylbutyrate (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Brexpiprazole